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Abstract
Background: Traumatic brain injury (TBI) induces primary and secondary damage in both the endothelium and
the brain parenchyma, collectively termed the neurovascular unit. While neurons die quickly by necrosis, a vicious
cycle of secondary injury in endothelial cells exacerbates the initial injury in the neurovascular unit following TBI. In
activated endothelial cells, excessive superoxide reacts with nitric oxide (NO) to form peroxynitrite. Peroxynitrite has
been implicated in blood brain barrier (BBB) leakage, altered metabolic function, and neurobehavioral impairment.
S-nitrosoglutathione (GSNO), a nitrosylation-based signaling molecule, was reported not only to reduce brain levels
of peroxynitrite and oxidative metabolites but also to improve neurological function in TBI, stroke, and spinal cord
injury. Therefore, we investigated whether GSNO promotes the neurorepair process by reducing the levels of
peroxynitrite and the degree of oxidative injury.
Methods: TBI was induced by controlled cortical impact (CCI) in adult male rats. GSNO or 3-Morpholino-
sydnonimine (SIN-1) (50 μg/kg body weight) was administered orally two hours following CCI. The same dose was
repeated daily until endpoints. GSNO-treated (GSNO group) or SIN-1-treated (SIN-1 group) injured animals were
compared with vehicle-treated injured animals (TBI group) and vehicle-treated sham-operated animals (Sham
group) in terms of peroxynitrite, NO, glutathione (GSH), lipid peroxidation, blood brain barrier (BBB) leakage, edema,
inflammation, tissue structure, axon/myelin integrity, and neurotrophic factors.
Results: SIN-1 treatment of TBI increased whereas GSNO treatment decreased peroxynitrite, lipid peroxides/
aldehydes, BBB leakage, inflammation and edema in a short-term treatment (4-48 hours). GSNO also reduced brain
infarctions and enhanced the levels of NO and GSH. In a long-term treatment (14 days), GSNO protected axonal
integrity, maintained myelin levels, promoted synaptic plasticity, and enhanced the expression of neurotrophic
factors.
Conclusion: Our findings indicate the participation of peroxynitrite in the pathobiology of TBI. GSNO treatment of
TBI not only reduces peroxynitrite but also protects the integrity of the neurovascular unit, indicating that GSNO
blunts the deleterious effects of peroxynitrite. A long-term treatment of TBI with the same low dose of GSNO
promotes synaptic plasticity and enhances the expression of neurotrophic factors. These results support that GSNO
reduces the levels of oxidative metabolites, protects the neurovascular unit, and promotes neurorepair mechanisms
in TBI.
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Neurobehavioral dysfunctions associated with traumatic
brain injury (TBI) are the consequences of oxidative
injury in the neurovascular unit that results in a dama-
ging progression. These pathological events include con-
tinuous production of reactive oxidizing species and
inflammation leading to disruption of the blood brain
barrier (BBB), altered tissue homeostasis, axon/myelin
loss, and cell death [1]. Previously, we reported the effi-
cacy of S-nitrosoglutathione (GSNO) in TBI (short-
term) [2], stroke [3,4] and spinal cord injury (SCI) [5].
In this report, we investigate the mechanisms of
GSNO’s action and test whether GSNO stimulates neu-
rorepair processes in a clinically relevant two-week long
TBI study.
GSNO, a modulator of cellular redox, is a physiologi-
cal metabolite produced by the reaction of nitric oxide
(NO) with glutathione (GSH) [6]. It is an efficient nitro-
sylating agent, and the mechanism of nitrosylation mod-
ulates protein functioning in health and disease [7,8].
Moreover, nitrosylation, like phosphorylation, functions
as a signaling pathway and plays a major role in regulat-
ing several physiological and pathological processes.
Under physiological conditions, GSNO and S-nitro-
sothiols are present in blood and brain [9-12]. The con-
centration of GSNO in adult rat brain tissue is
estimated to be 6-8 μM ,w h i c hi s~ 0 . 3t o0 . 7 %o ft h e
tissue GSH level [10]. A study on GSNO metabolism
and its membrane crossing ability has been reported
[13]. Using an in vitro BBB model, we have also
reported that significant levels of GSNO cross the cellu-
lar membrane [3].
Pharmacologically, GSNO has been shown to protect
the central nervous system (CNS) against excitotoxicity,
inflammation, and reactive oxygen species (ROS) in a
variety of injury conditions [14]. GSNO invokes its anti-
inflammatory effects on post-injury events mainly
through the down regulation of the expression of NF-
B, adhesion molecules, cytokines and inducible NOS
(iNOS) [2,3,15-17]. It exerts its neuroprotective effects
via reducing the neuronal apoptotic cell death and inhi-
biting the activity of caspase-3 [2,3]. GSNO shows its
antioxidant action through the modulation of redox
[18], such as increasing glutathione (GSH) [4] and
decreasing peroxynitrite levels [19-21]. In acute CNS
injury animal models, GSNO protects BBB, decreases
edema, and reduces the expression of ICAM-1, ED1,
and MMP-9 [2]. Furthermore, GSNO inhibits platelet
activation, reduces embolization in humans [22-26], and
inhibits inflammatory events in endothelial [17] and T
cells [27]. Nitrosylation’s protective effect in heart dis-
ease has also been observed [22,28,29]. Deficient nitrosy-
lation seems to be a general mechanism of disease
pathogenesis [30]. However, the potential of GSNO to
stimulate the neurorepair process in human or animal
brain trauma models, such as TBI, has not been
investigated.
To investigate the GSNO-mediated mechanisms of
neurorepair, we used a rat controlled cortical impact
(CCI) model because approximately 40% of all TBIs are
contusions [31]. The rat model of TBI using the focal
CCI technique is recognized as physiologically relevant
to human TBI [32]. It reproduces many of the features
of human brain injuries including inflammation, BBB
disruption, neuron loss, motor deficit, and compromised
memory [33].
Presently, effective therapy for TBI patients is not
available, mainly because of the limited understanding
of the crosstalk between the multiple pathways involved
in acute and chronic phases of the injury [1]. Delinea-
tion of these mechanisms is complicated due, in part, to
excessive production of reactive oxygen/nitrogen species
(ROS/RNS), not only in the brain cells but also in the
endothelial cells. The involvement of ROS/RNS is sup-
ported by the observed reduced damage and improved
brain functions afforded by free radical trapping agents
and antioxidants in TBI [1,34-37] and stroke [38,39].
One of the highly deleterious ROS/RNS is peroxynitrite,
a reaction product of a diffusion limited, instantaneous
reaction between superoxide and NO. Peroxynitrite is
documented to be highly injurious, and its reduction
yields neuroprotection following experimental TBI and
ischemia reperfusion (IR) injury [35,40-42]. Hence, 3-
morpholino sydnonimine (SIN-1), a peroxynitrite form-
ing agent, is deleterious in animal models of TBI [43]
and stroke [4]. Treatment with GSNO has been shown
to decrease the levels of peroxynitrite following brain
injury [4,20]. GSNO also reduces inflammation, protects
neurons from apoptotic cell death, and improves neuro-
behavioral functions following TBI [2], SCI [5], and IR
[3,4]. However, the mechanisms through which GSNO
reduces peroxynitrite, stimulates the neurorepair pro-
cess, and improves neurobehavioral function are not
clear.
In TBI, reduced NO bioavailability in the neurovascu-
lar unit is recognized to be the consequence of its con-
version to peroxynitrite. Once formed, peroxynitrite can
‘uncouple’ endothelial NOS (eNOS) via oxidation and
thus depleting the eNOS substrate L-arginine, the cofac-
tor tetrahydrobiopterin (BH4), or both [44,45]. Excessive
production of peroxynitrite can lead to endothelial cell
activation and up regulation of ICAM-1 in such an oxi-
dative microenvironment, thus compromising BBB
integrity and contributing to edema [41]. Peroxynitrite is
a highly reactive species for the nitration and inactiva-
tion of tyrosine in proteins in biological systems [46].
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hydroxyl radical [47]. Reducing iron or neutralizing ROS
has been shown to be neuroprotective, indicating that
iron and ROS play significant role in peroxynitrite-
induced brain injury [48]. Antioxidant therapy down
regulates neuroinflammation, stimulates the neurorepair
process, and reduces neurological deficits following TBI
[34,49].
In this study, we demonstrated that post-injury
administration of GSNO reduced the oxidative injury in
the neurovascular unit caused by peroxynitrite and its
metabolites. The injury was associated with BBB leakage,
neuroinflammation, edema, depletion of GSH and NO,
and reduced expression of neurotrophic factors.
Increased BBB leakage and edema, and an enhanced
mRNA expression of ICAM-1 in the SIN-1 group com-
pared to the TBI group indicate the involvement of per-
oxynitrite in BBB pathology. These results are supported
by the increased formation of peroxynitrite and lipid
peroxide/aldehydes and decreased levels of NO and
GSH in the SIN-1 group. Moreover, a long-term (2-
week) treatment with GSNO not only inhibited the loss
of myelin and axons, but also enhanced the expression
of neurotrophic factors. These findings indicate that
GSNO not only down regulates TBI-induced neurovas-
cular exacerbations but also stimulates the mechanisms
of neurorepair.
Methods
Reagents
GSNO was purchased from World Precision Instru-
ments (Sarasota, FL). 3-Morpholino-sydnonimine
(SIN-1) was obtained from Cayman Chemical (Ann
Arbor, MI). All other chemicals and reagents used were
purchased from Sigma-Aldrich (St. Louis, MO), unless
stated otherwise.
Animals
Male Sprague-Dawley rats weighing 240-260 g (Harlan
Laboratories, Wilmington, MA) were used in this study.
All animal procedures werea p p r o v e db yt h eM e d i c a l
University of South Carolina Animal Review Committee
and received humane care in compliance with the Medi-
cal University of South Carolina’s experimental guide-
lines and the National Research Council’s criteria for
humane care (Guide for the Care and Use of Laboratory
Animals). Animals were not allowed to fast at any time
in this study.
Experimental design and administration of GSNO
The rats were randomly allocated into five groups: i)
Sham (sham-operated control, n = 30); ii) TBI (vehicle-
treated CCI, n = 40); iii) GSNO (GSNO-treated CCI, n
= 40); iv) SIN-1 (SIN-1-treated CCI, n = 28); and v)
Control (untreated normal, n = 13). Because GSNO-
treated sham animals had no altered physiologic para-
meters (Table 1), including mean arterial blood pressure
(MABP) and heart rate (HR), we did not include the
Sham+GSNO group for further study. In the GSNO and
SIN-1 groups, the rats were given freshly prepared
GSNO (50 μg/kg body weight) and SIN-1 (50 μg/kg
body weight), respectively, dissolved in sterile saline
(~300 μl) by mouth using gavage needle at 2 hours after
CCI. The rats in the TBI and the Sham groups were
administered the same volume of saline. The same dose
of GSNO and SIN-1 was repeated once every 24 hours
by mouth until the endpoint (maximum 2 weeks) as
described under each experiment. The dosages of both
GSNO and SIN-1 used in this study were determined by
ad o s er e s p o n s ec u r v er a n g i n gf r o m1 0μgt o1 0 0μg/kg
body weight. The dose 50 μg/kg was found to be the
most effective in reducing contusion volume measured
at 7 days after CCI, as described in our previous TBI
study [2]. The selected dosages of both GSNO and SIN-
1 did not alter physiologic parameters including MABP,
HR, and temperature, measured at 1 hour following
GSNO or SIN-1 treatment (Table 1). Similar observa-
tions with low dose GSNO treatments were made in
our TBI [2], SCI [5], and IR studies [3,4]. Blood pressure
and HR were non-invasively measured by determining
Table 1 Physiologic parameters
Sham Injured (CCI)
Untreated GSNO-treated SIN-1-treated Untreated (TBI) GSNO-treated (GSNO) SIN-1 treated
(SIN-1)
Basal 3 h Basal 3 h Basal 3 h Basal 3 h CCI Basal 3 h CCI Basal 3 h CCI
Rectal
Temp (°C)
37.3 ± .3 37.2 ± .2 37.3 ± .2 36.9 ± .2 37.2 ± .1 36.8 ± .4 37.3 ± .2 36.6 ± .4 37.3 ± .3 36.7 ± .2 37.3 ± .2 36.6 ± .3
MABP (mm Hg) 123 ± 12 121 ± 11 122 ± 10 120 ± 12 122 ± 12 119 ± 13 121 ± 12 97 ± 14 116 ± 10 95 ± 9 118 ± 7 91 ± 8
HR (beat/min) 396 ± 32 394 ± 31 394 ± 32 404 ± 35 395 ± 31 408 ± 29 395 ± 30 405 ± 25 382 ± 27 410 ± 40 385 ± 24 415 ± 30
Measurements were performed before CCI (basal) and at 3 hours after CCI or 1 hour after drug administration (50 μg/kg body weight, oral). Data are presented
as mean ± SD for n = 5 animals in each group. No significant differences were observed among untreated and treated groups of sham or injured animals.
However, animals after CCI showed a trend of decreased MABP in the injured group. Basal, 30 min before CCI; Temp, temperature; MABP, mean arterial blood
pressure; HR, heart rate.
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(VPR) sensor and an occlusion tail-cuff (CODA System,
Kent Scientific, Torrington, CT).
Controlled cortical impact (CCI) model of TBI
Surgical anesthesia was induced by ketamine (90 mg/kg
body weight) and xylazine (10 mg/kg body weight)
administered intraperitoneally (ip). Analgesic buprenor-
phine was administered pre-emptively to alleviate the
pain following surgery. Utilizing aseptic techniques, a
midline scalp incision was made, and the skin and fascia
were reflected to expose the skull. A craniotomy was
made in the right hemisphere, encompassing bregma
and lambda, and between the sagittal suture and the
coronal ridge with a handheld Michele trephine. The
resulting bone flap was removed, and the craniotomy
enlarged further with cranial rongeurs. This process did
not cause rupture or significant bleeding. CCI injury
was produced as previously described in the extensive
literature [50-55]. A cortical contusion was produced on
the exposed cortex using either a controlled impactor
device described by Bilgen [56] and previously used in a
rat model of SCI [5,57], or a TBI-0310 TBI Model sys-
tem (Precision Systems and Instrumentation, LLC, Fair-
fax Station, VA) as described in our TBI study [2].
Briefly, the impacting shaft was extended, and the
impact tip was centered and lowered over the craniot-
omy site until it touched the dura mater. Then, the rod
was retracted and the impact tip was advanced farther
to produce a brain injury of moderate severity (tip dia-
meter, 4 mm; cortical contusion depth, 3 mm; impact
velocity, 1.5 m/sec) [2]. The impact tip was wiped clean
with sterile alcohol after each impact and cleaned/disin-
fected further with cidex after surgery. Core temperature
was maintained at 37 ± 0.5°C with a heating pad during
surgery and recorded with a rectal probe. Immediately
after injury, the skin incision was closed with nylon
sutures without replacing the bone flap. Lidocaine jelly
(2%) was applied to the lesion site to minimize any pos-
sible infection/discomfort.
Evaluation of BBB disruption by Evan’s blue (EB)
extravasation
BBB leakage was assessed as described [2] by the
method of Weismann and Stewart [58] with slight mod-
ification. The rats received 100 μl of a 5% solution of EB
in saline administered intravenously 4 hours following
CCI. At 48 hours, cardiac perfusion was performed
under deep anesthesia with 200 ml of saline to clear the
cerebral circulation of EB. The brain was removed,
s l i c e d ,a n dp h o t o g r a p h e d .T h et w oh e m i s p h e r e sw e r e
isolated and mechanically homogenized in 750 μlo fN ,
N-dimethylformamide (DMF). The suspension obtained
was kept at room temperature in the dark for 72 hr. It
was centrifuged at 10,000 × g for 25 minutes, and the
supernatant was spectrofluorimetrically analyzed (lex
620 nm, lem 680 nm) to determine EB content.
Measurement of Edema (brain water content)
At 24 h following CCI, animals were euthanized to
determine brain water content (edema) as described ear-
lier [2,59]. The cortices, excluding the cerebellum, were
quickly removed, and the contralateral and ipsilateral
hemispheres separately weighed. Each hemisphere was
dried at 60°C for 72 hours, and the dry weight was
determined. Water content was calculated in ipsilateral
hemisphere as: water content (%) = (wet weight - dry
weight)/wet weight × 100.
Dot blot analysis
D o tb l o tf o rt h ee x p r e s s i o no f3 - N Ta n db-actin in the
traumatic penumbra region was performed as described
by Neumann et al [60]. In brief, PVDF membranes were
hydrated in TBS and then placed in a Bio-Dot microfil-
tration. Wells were washed with 100 μlo fT B Su n d e ra
partial vacuum. Wells were loaded with 100 μg( 7 5μl)
protein each. The membrane was washed in TBS and
blocked 30 min in blotto (TBS, 5.0% non-fat dry milk,
0.05% Tween 20) at room temperature. The membrane
was then incubated with monoclonal anti-nitrotyrosine
antibody (Abcam, Cambridge, MA; dilution 1:1000), or
anti-b-actin antibody in blotto for 3 h at room tempera-
ture. The blot was washed in TTBS (TBS, 0.05% Tween
20). The blot was then incubated with a secondary anti-
b o d yf o r4 5m i na n dw a s h e di nT T B S3t i m e sf o r5
minutes. The blot was developed as described elsewhere
for Western blot [2]. The bands were quantitated using
a GS-800 calibrated densitometer from Bio-Rad Labora-
tories (Hercules, CA, USA). Protein concentrations were
determined using protein assay dye from Bio-Rad
Laboratories (Hercules, CA).
Histopathology, inflammation, and demyelination
Histological evaluation was done on paraformaldehyde-
fixed, paraffin-embedded sections (4 μM) of brain. Sec-
tions were stained with hemotoxylin and eosin (H&E),
luxol fast blue (LFB), and Bielshowsky silver impregna-
tion to assess inflammation, demyelination, and axonal
pathology, respectively. H&E and LFB staining were per-
formed as described previously from our laboratory [61].
For Bielschowsky silver immunostaining, slides were
placed in 20% silver nitrate in the dark, and then
sodium hydroxide and sodium thiosulfate were added to
the slides in turn as described earlier [62]. The histologi-
cal analysis was performed by an investigator who was
blinded to the experimental groups.
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Paraffin-embedded sections from the formalin-fixed
brain tissues were stained for 3-NT, 4-HNE, ferritin,
von Willebrand factor (vWF), platelet endothelial cell
adhesion molecule 1 (PECAM-1), NeuN, synaptophysin,
BDNF, and TrkB as described previously [2]. In brief,
the brain tissue sections were deparaffinized, sequen-
tially rehydrated in graded alcohol, and then immersed
in PBS (pH 7.4). Slides were then microwaved in anti-
gen unmasking solution (Vector Labs), cooled, and
washed 3 times for 2 minutes in PBS. Sections were
incubated overnight with antibodies of 3-NT, NeuN,
synaptophysin, BDNF, TrkB, ferritin (abcam, Cambridge,
MA), 4-HNE (A. G. Scientific, San Diego, CA), vWF,
and PECAM-1 (Santa Cruz Biotechnology, Santa Cruz,
CA). They were then rinsed 3 times for 5 minutes in
PBS containing 0.1% Tween-20. Secondary anti-rabbit
and mouse IgG, conjugated with Alexa Fluor 568 and
488, respectively, were incubated on slides for 60 min-
utes. BDNF sections were allowed to react with anti-
mouse IgG conjugated to a peroxidase-labeled dextran
polymer (for 60 min) and then developed with diamino-
benzidine substrate for 10 min at room temperature.
All sections were examined for immunoreactivity in the
traumatic penumbral area using an Olympus micro-
scope equipped for epifluorescence and DP Controller
software. Figures were compiled in Adobe Photoshop
software.
For double labeling, sections were incubated first with
an antibody of 3-NT followed by specific cell marker
antibodies (vWF, NeuN, or PECAM-1). For immuno-
fluorescent double-labeling, immune complexes were
visualized with Texas Red conjugated anti-rabbit IgG
(1:100, Vector Labs) and FITC conjugated anti-mouse
IgG (1:100, Vector Labs). Rabbit polyclonal IgG was
used as a control primary antibody. In another set of
experiments, sections were also incubated with FITC or
Texas Red conjugated IgG without the primary antibody
as a negative control to confirm the specificity of the
primary antibody. Slides were examined for immuno-
fluorescence using an Olympus microscope equipped
with an epifluorescence filter and Adobe Photoshop
software [3].
Semi-quantitative cell counting was performed in
three equi-distant sections (10 sections apart) from each
brain and expressed as an average number of immuno-
positive cells per section. The positive cells were
counted on each section at 400 × magnification (one
visual field = 0.69 mm
2) using an Olympus microscope
equipped with epifluorescence and DP Controller soft-
ware. Images were captured and processed using Adobe
Photoshop software.
Real-time polymerase chain reaction (RTPCR)
Total RNA from the traumatic penumbra was isolated
with TRIZOL (Invitrogen, Carlsbad, CA) according to
the manufacturer’s protocol. RTPCR was conducted
using Bio Rad iCycler (iCycler iQ Multi-Color Real
Time PCR Detection System; Bio Rad, Hercules, Califor-
nia). Single stranded cDNA was synthesized from total
RNA isolated from sham, TBI, GSNO, and SIN-1-trea-
t e db r a i n sa t2 4ha n d1 4d a y sf o l l o w i n gT B Iu s i n gt h e
superscript pre-amplification system for first strand
cDNA synthesis (Invitrogen, Carlsbad, CA) as described
earlier [63]. The primer sets used were designed by
using free software available at http://www.idt.com and
were purchased from Integrated DNA technologies
(IDT, Coralville, IA). The primer sequences were as fol-
lows: for intercellular adhesion molecule 1 (ICAM-1),
forward primer: 5’-GTCCTTCACACTGAATGCCAGC-
3’; reverse primer: 5’-TTAAACAGGAACTTTCCCGC-
CACC-3’, b- a c t i n ,f o r w a r dp r i m e r :5 ’-AGCTGTGC-
TATGTTGCCCTAGACT-3’; reverse primer: 5’-
ACCGCTCATTGCCGATAGTGATGA-3’.I Q ™ SYBR
Green Supermix was purchased from Bio-Rad (BIO-
RAD Laboratories, Hercules, CA). Thermal cycling con-
ditions were as follows: activation of iTaq TM DNA
polymerase at 95°C for 10 min, followed by 40 cycles of
amplification at 95°C for 30 sec and 55-57.5°C for 30 -
60 seconds. The detection threshold was set above the
mean base line fluorescence determined by the first 20
cycles. Amplification reaction in which the fluorescence
increased above the threshold was defined as positive. A
standard curve for each template was generated using
serial dilution of the template (cDNA). The quantities of
target gene expression were normalized to the corre-
sponding b-actin mRNA quantities in test samples.
Evaluation of infarction using TTC staining
To evaluate infarct, a 2, 3, 5-triphenyltetrazolium chloride
(TTC) staining technique was used followed by image
acquisition by computer. Briefly, after an overdose of pen-
tobarbital, the rats were killed by decapitation at 48 h of
CCI. The brains were quickly removed and placed in ice-
cold saline for 5 min. Six serial sections from each brain
were cut at 2-mm intervals from the frontal pole using
rodent brain matrix (ASI Instrument Inc., Warren, MI).
The sections were incubated in 2% TTC saline solution
for 15 min at 37°C. The stained brain sections were stored
in 10% formalin and refrigerated at 4°C for further proces-
sing and storage. Coronal sections (2 mm) were placed on
a flat bed color scanner (HP scan jet 5400 C) connected to
a computer. The infarct area, outlined in white, was
acquired by image-analysis software (Adobe Photoshop
software) and measured by NIH image software.
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The plasma samples collected at 4 h of CCI were quan-
tified for nitrotyrosine by BIOXYTECH
® Nitrotyrosine
-EIA kit from Oxis Research (Portland, OR) per the
manufacturer’s instructions and as described previously
[4]. Briefly, 100 μl of samples (diluted 10 times in the
dilution buffer) were added to each well of a precoated
plate for 1 h at room temperature. After four washes
with wash buffer, nitrotyrosine antibody was added to
each well and incubated at room temperature for 1 h.
Subsequently, streptavidin peroxidase was added and the
plate incubated for 1 h at room temperature. Tetra-
methylbenzidine (TMB) substrate was added, and the
plate was incubated in the dark at room temperature to
complete the reaction. The optical density of the assay
samples was measured spectrophotometrically at 450
nm using SpectraMax 190 (Molecular Devices, San
Diego, CA). A standard curve derived from nitrotyrosine
standards (provided with the kit) was used to calculate
the nitrotyrosine concentrations.
Measurement of NO in plasma
The plasma samples collected at 4 h of CCI were quan-
tified for the levels of NO using a Nitric Oxide fluoro-
metric assay kit from BioVision (Exton, PA). Briefly, 2 μl
plasma was used to assay NO (measured as the concen-
tration of nitrite and nitrate as an index of NO levels)
by 2, 3-diaminonaphthalene (DAN) reaction, using a
fluorometer (Ex. 360 nm and Em. 450 nm) per manu-
facturer’s instructions. Nitrate reductase was used to
convert nitrate in nitrite. Nitrite concentrations (NO
levels) were calculated from a standard curve derived
from sodium nitrite (provided with the kit).
Estimation of lipid peroxidation products in plasma
The plasma samples (100 μl/assay) collected at 4 h of
CCI were quantified for thiobarbituric acid reactive sub-
stances (TBARS) using a TBARS assay kit from Zepto-
Metrix Corporation (Buffalo, NY) per manufacturer’s
instructions and as described previously [4]. TBARS
were quantitated spectrophotometrically at 532 nm. A
standard curve derived from malondialdehyde (MDA)
was used to calculate the level of TBARS.
Measurement of the ratio GSH:GSSG
The levels of total glutathione (GSH and GSSG) were
measured at 24 h in the penumbra using a BIOXY-
TECH
® GSH/GSSG-412™ colorimetric assay kit from
Oxis Research (Portland, OR). The kit uses 5, 5’-dithio-
bis-2-nitrobenzoic acid (DTNB) and glutathione reduc-
tase as described by Tietze [64] with some modification.
It uses 1-methyl-2-vinylpyridinium trifluoromethanesul-
fonate (M2VP) instead of N-ethylmaleimide (NEM).
Brain tissues harvested at 24 h of CCI were minced and
homogenized (g/10 ml) in 5% metaphosphoric acid. The
procedure was followed per manufacturer’s instructions
and has been used in our previous studies [4,65]. The
levels were quantitated as μMG S Ho rG S S Gb a s e do n
standards supplied with the kit. Total GSH (TGSH)
levels were the sum of GSH and GSSH.
Statistical evaluation
Statistical analysis was performed as described [66]
using software Graphpad Prism 3.0. Unless otherwise
stated, all the values are expressed as mean ± SD of n
determinations or as mentioned. The results from bio-
chemical and animal behavior studies were examined by
unpaired Student t-test. Multiple comparisons were per-
formed using the Kruskal-Wallis test, or using ANOVA
followed by the Bonferroni test as appropriate. A p
value less than 0.05 was considered significant.
Results
Peroxynitrite is formed in and around the vessels after
TBI, and GSNO treatment reduces the expression of
peroxynitrite
We have previously reported that GSNO protects not
only the neurovascular unit after TBI and stroke [2-4]
but also reduces the levels of peroxynitrite in plasma
following IR [4]. Therefore, we investigated whether
GSNO also reduces the levels of peroxynitrite, measured
as the expression of 3-nitrotyrosine (3-NT) in TBI.
Because peroxynitrite is unstable, its detection through
3-NT expression is an index of the levels of peroxyni-
trite [67]. The expression of 3-NT was measured at 4 h
following TBI in the traumatic penumbra region using
d o tb l o t[ 6 0 ]a n dI H C .G S N O( 5 0μg/kg body weight)
treatment significantly reduced the TBI-mediated
increased expression of 3-NT as shown by dot blotting
(Figure 1A) and its densitometry (Figure 1B). A similar
decrease of the expression of 3-NT by GSNO was also
observed using IHC (Figure 1C). The expression was
remarkable in and around vessels as indicated by its
colocalization with vWF, an endothelial cell marker
(Figure 1D). However, the expression of 3-NT at 4 h
was not observed in other cell types, including neurons
(data not shown). In a long-term study (2-week), the
expression of 3-NT was found to be remarkably
increased in the traumatic penumbra (Figure 2A). After
two weeks, the expression of 3-NT was observed in
both neurons (Figure 2B) and endothelial cells (Figure
2C) as indicated by colocalization of 3-NT with NeuN
(neuronal cell marker) and PECAM-1 (endothelial cell
marker), respectively. Treatment with GSNO decreased
the expression of 3-NT (Figure 2A). In long-term study,
PECAM-1 was used as an endothelial cell marker
because it detects mature endothelial cells.
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plasma following TBI
To test whether GSNO decreases and SIN-1 (a peroxy-
nitrite forming agent) increases TBI-mediated accumula-
tion of peroxynitrite in plasma and whether the plasma
levels correlate with the tissue levels, we determined 3-
NT levels in plasma at 4 h in TBI, GSNO, and SIN-1
groups. The selected dose (50 μg/kg body weight) of
GSNO and SIN-1 did not alter any of the physiologic
parameters, including rectal temperature, MABP, and
Figure 1 Effect of GSNO on the expression of 3-NT determined by dot blot and IHC at 4 h after TBI and colocalization of 3-NT with vWF.
Animals were treated with GSNO (50 μg/kg body weight) at 2 h after TBI. Dot blot (A) and its densitometric analysis (B), performed at 4 h after TBI,
show the accumulation of 3-NT in the traumatic penumbra region. The expression of 3-NT was significantly reduced in the GSNO group.
Photomicrographs of IHC of 3-NT (C), determined at 4 h after TBI, show the enhanced expression of 3-NT in and around vessels. Treatment with
GSNO reduced the TBI-mediated increased expression of 3-NT. Colocalization of 3-NT with an endothelial cell marker vWF as yellowish fluorescence
(D) indicates that 3-NT was expressed in endothelial cells. Dot blots (A, B) and photomicrographs (C, D) are representative of n = 3 in each group.
Densitometry results (B) are expressed as fold change, and data are presented mean ± SD. *p < 0.05 vs. Sham and GSNO.
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Page 7 of 17HR (Table 1). A similar dose of GSNO provided the
neurovascular protection as reported previously [2].
While GSNO treatment significantly reduced the TBI-
mediated levels of 3-NT, SIN-1 significantly increased
the levels (Figure 3A). SIN-1 treatment also significantly
increased the levels of 3-NT compared with TBI. These
results agree with a published report showing increased
levels of 3-NT after SIN-1 treatment [42]. Furthermore,
the levels of 3-NT in plasma (Figure 3A) had a correla-
tion with the observed increased expression of 3-NT in
the traumatic penumbra (Figure 1).
GSNO increases and SIN-1 decreases the levels of NO in
plasma following TBI
Peroxynitrite is formed instantaneously through a diffu-
sion limited reaction between superoxide and NO, result-
ing in decreased levels of NO [67]. We determined
whether increased levels of peroxynitrite corresponded to
Figure 2 Effect of GSNO on reduction of the expression of 3-NT at 14
th day after TBI. Photomicrographs of IHC show enhanced reaction
of 3-NT (red color) in the traumatic penumbra region of TBI compared to GSNO group. Sham brain does not show 3-NT-positive cells.
Colocalization (yellowish, merged) of 3-NT (red color) with either neuronal marker NeuN (green) (B) or endothelial cell marker PECAM-1 (green)
(C) indicates that both neurons and endothelial cells have significantly increased expression of 3-NT even after 14 days of TBI. Photomicrographs
are representative of n = 3 in each group.
Figure 3 Effect of GSNO and SIN-1 on levels of 3-NT and NO in
plasma at 4 h after TBI. Levels of 3-NT (A) and NO (B) were
measured in plasma using colorimetric and fluorometric assay kits,
respectively. While GSNO treatment of TBI decreased, the SIN-
1treatment increased the levels of 3-NT (A). GSNO treatment also
increased the levels of NO, whereas SIN-1 treatment did not alter
the levels of NO in the injured animals. Results are expressed as nM
for 3-NT and μmol/L for NO. Data are presented as mean ± SD of
triplicate determinations from five different experiments. ***p <
0.001 vs. Control, Sham, GSNO, +p < 0.05 vs. TBI.
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plasma samples at 4 h following TBI. While GSNO treat-
ment significantly increased the TBI-mediated decreased
levels of NO, SIN-1 significantly decreased the levels (Fig-
ure 3B). SIN-1 treatment also significantly decreased the
levels of NO compared with the TBI plasma. Expectedly,
the levels of NO in plasma had an inverse relationship
with the levels of 3-NT in plasma (Figure 3A-B).
GSNO decreases and SIN-1 increases the levels of TBARS
in plasma, and GSNO also reduces the expression of 4-
HNE and ferritin in the traumatic penumbra region
following TBI
In addition to nitration and inactivation of the tyrosine
residue of a protein forming 3-NT, peroxynitrite is
implicated in tissue injury via lipid peroxidation [47].
Peroxynitrite forms a highly reactive hydroxyl radical in
the presence of free iron. Ferritin is a key iron storage
protein, and its expression is increased in the presence
of free iron [68]. Therefore, we determined the levels of
the lipid peroxidation products TBARS (Figure 4A) in
plasma and the expression of 4-HNE (Figure 4B) in the
traumatic penumbra at 4 h following TBI. We also mea-
sured the expression of ferritin (Figure 4C), supporting
that decomposition of peroxynitrite due to the presence
of excessive free iron may be responsible for the
increased levels of lipid peroxidation products. Like its
effect on 3-NT (Figure 3A), the GSNO treatment signifi-
cantly reduced the TBI-mediated accumulation of
TBARS in plasma (Figure 4A). Contrary to GSNO’s
Figure 4 Effect of GSNO and SIN-1 on levels of TBARS in plasma and on the expression of 4-HNE and ferritin in the traumatic
penumbra region at 4 h after TBI. Levels of TBARS were measured in plasma using TBARS assay kit. While GSNO treatment of TBI decreased,
the SIN-1 treatment increased the levels of TBARS (A). TBARS results are expressed as nmol/ml plasma, and data are presented as mean ± SD of
triplicate determinations from five different experiments. ***p < 0.001 vs. Control, Sham, GSNO, +p < 0.05 vs. TBI. The expression of 4-HNE (B)
and ferritin (C) was determined using IHC. Photomicrographs show enhanced reaction of both 4-HNE and ferritin in the traumatic penumbra
compared to GSNO group. Sham brain does not show significant number of 4-HNE or ferritin-positive cells. Photomicrographs are representative
of n = 3 in each group.
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the levels of TBARS (Figure 4A). Remarkably, SIN-1
treatment increased the levels of TBARS even further
than TBI (p < 0.05), indicating peroxynitrite participa-
tion in lipid peroxidation. Similar to the effect of GSNO
on TBARS (Figure 4A) and 3-NT (Figure 3A) in plasma,
the treatment also reduced the expression of 4-HNE in
the traumatic penumbra (Figure 4B). GSNO treatment
of TBI also reduced the expres s i o no ff e r r i t i n( F i g u r e
4C), indicating that the GSNO treatment down regu-
lated the overall oxidative burden.
GSNO decreases and SIN-1 increases BBB leakage and
edema following TBI
BBB disruption and edema indicate pathology associated
with endothelial cell activation and endothelial dysfunc-
tion [69]. Peroxynitrite, through 3-NT formation, has
been implicated in cerebral vascular dysfunction and the
consequent BBB disruption [41,70,71]. In contrast, the
nitrosylating agent GSNO has been shown to reduce
B B Bl e a k a g ea n de d e m a[ 2 ] ,a n dt op r o v i d ep r o t e c t i o n
to neurons and vessels [4,18,20]. To compare the neuro-
vascular protective action of GSNO/nitrosylation and
the deleterious action of SIN-1/3-NT, we examined the
effect of GSNO and SIN-1 on BBB leakage and edema
following TBI. Extravasations of Evan’s blue dye into the
brain of TBI were higher than in the GSNO brain
(Figure 5A-B). Unlike the effect of GSNO, treatment
with SIN-1 increased Evan’s blue extravasations. More-
over, the SIN-1 mediated extravasations were greater
than TBI, indicating that peroxynitrite causes neurovas-
cular oxidative injury. A study of edema at 24 h after
TBI showed increased levels of water content in the TBI
brain (Figure 5C). While the treatment with GSNO
decreased the water content, SIN-1 treatment increased
it, again beyond the levels in the TBI brain. This
comparative study of GSNO and SIN-1 on BBB integrity
indicates that the nitrosylating agent GSNO provides
neurovascular protection and the peroxynitrite-produ-
cing agent SIN-1 worsens injury.
GSNO down regulates mRNA expression of ICAM-1in the
traumatic penumbra region following TBI
ICAM-1 mediates endothelial dysfunction that facilitates
BBB leakage, resulting in the transmigration of blood-
derived immune cells in the brain and thereby maintain-
ing a persistent inflammation following TBI [72]. There-
fore, we determined whether TBI-mediated increased
mRNA expression of ICAM-1 is decreased at both
short- and long-term GSNO treatment, thus reducing
inflammation and stimulating the mechanisms of neu-
rorepair. The traumatic penumbra region had increased
mRNA levels of ICAM-1 at both 24 h (Figure 6A) and
14 days (Figure 6B) following TBI. GSNO treatment
prevented the increase in mRNA levels of ICAM-1,
whereas the treatment with SIN-1 increased the levels at
both 24 h and 14 days (Figure 6). The sham-operated
brain had no significant mRNA levels of ICAM-1.
GSNO reduces brain infarctions following TBI
Directly related to overall brain injury, measurement of
brain infarctions is a standard method to evaluate
ischemic injury after stroke [73]. Previous study shows
that treatment with GSNO reduces infarctions following
IR [3] and inhibits apoptotic cell death following TBI
[2]. To evaluate the effect of GSNO on brain infarctions
in the TBI brain, we performed TTC staining (Figure
7A) and measured the infarct area (Figure 7B). The
infarctions were significantly reduced after treatment
with GSNO (Figure 7A-B). Measuring infarctions also
served the purpose of locating the traumatic penumbra
as shown by a rectangle on the GSNO section (Figure
Figure 5 Effect of GSNO and SIN-1 on BBB leakage and edema. Photographs showing Evan’s blue (EB) extravasations in five coronal sections
of brain starting at 4 h after TBI. Animals were sacrificed at 48 h, the brain was sectioned and photographed (A) and the intensity of EB (B) was
determined by spectrofluorometric estimation. EB extravasations were not observed in sham brain, hence the photographs of sham brain are
not shown. Edema (C) was measured at 24 h after TBI. While GSNO treatment of TBI decreased, SIN-1treatment increased both the Evan’s blue
extravasations and edema. Data are expressed as mean ± SD from five different experiments. ***p < 0.001 vs. TBI and SIN-1, *p < 0.05 vs. TBI.
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histological studies.
GSNO increases and SIN-1 decreases the levels of both
reduced glutathione (GSH) and total glutathione (TGSH;
GSH+GSSG) in the traumatic penumbra region following
TBI
G S Hi sa ne n d o g e n o u sa n t i o x i d a n tt h a tp r o t e c t s
endothelial function and improves NO bioavailability in
the neurovascular unit following acute injury [74]. With
NO and oxygen, GSH forms GSNO [75], and GSNO is
metabolized into GSSG (oxidized GSH) during nitrosyla-
tion in vivo [6,10]. We tested whether GSNO, a strong
antioxidant against peroxynitrite [20], increased, and
whether SIN-1, a strong oxidant [43], decreased the
levels of GSH and TGSH. The TBI brain had signifi-
cantly lower levels of both GSH and TGSH than con-
trol, sham, and GSNO brains measured at 24 h
following CCI (Figure 8). However, the SIN-1-treated
brain had significantly reduced levels of both compared
to even the TBI brain (Figure 8). These results show
that peroxynitrite causes its deleterious effects, at least
in part, by reducing the levels of GSH.
GSNO protects the integrity of brain tissue and axons,
and enhances the levels of myelin following TBI
To examine whether GSNO treatment of TBI maintains
tissue structure and aids the neurorepair process, tissue
histology using H&E (Figure 9A), myelin content using
LFB (Figure 9B), and axonal integrity using Bielschowsky
silver (Figure 9C) stainings were performed in the fixed
sections at 14 days after TBI. H&E staining shows that
TBI-mediated tissue deformation and infiltration of
immune cells were blocked by GSNO treatment.
Furthermore, myelin levels were reduced following TBI
(Figure 9B). GSNO treatment also reduced the loss of
myelin, indicating an induction of the neurorepair pro-
cess. Bielschowsky silver staining is a marker of axonal
integrity, which was also reduced in TBI (Figure 9C).
The treatment with GSNO protected axonal integrity, as
indicated by the enhanced staining of Bielschowsky sil-
ver in the GSNO brain.
Figure 7 Effect of GSNO on reduction of infarction after TBI.
Representative TTC-stained brain section (#3 out of the six
consecutive sections from cranial to caudate region) corresponding
to the largest infarction (A) and infarct area (B) from each group.
Brain sections (2 mm thick) were stained with TTC at 48 h after CCI
to show the area of infarctions. The infarctions were not observed
in the sham group. The area under the rectangle on GSNO section
was used for IHC and histology studies. Data are presented as
means ± SD from three different experiments. *** p < 0.001 vs. TBI.
Figure 8 Effect of GSNO and SIN-1 on levels of reduced
glutathione (GSH) and total glutathione (TGSH; GSH+GSSG) in
the traumatic penumbra at 24 h after TBI. Levels of GSH and
GSSG were measured in plasma using a colorimetric assay kit. Results
are expressed as nmol/mg wet tissue, and data are presented as
mean ± SD of triplicate determinations from five different
experiments. ***p < 0.001 vs. Control, Sham, GSNO, +p < 0.05 vs. TBI.
Figure 6 Effect of GSNO and SIN-1on reduction of mRNA
expression of ICAM-1 in brain at 24 h and 14
th day after TBI.
RNA was isolated from Sham, TBI, GSNO and SIN-1 treated traumatic
penumbra region at 24 h (A) and 14
th day (B) after TBI. Levels of
ICAM-1 were determined by RT-PCR and normalized with b-actin.
While GSNO treatment decreased, SIN-1 treatment increased ICAM-1
levels at both 24 h (A) and 14 days (B). Data are presented as mean
± SD (fold change) of duplicate determinations from three different
experiments. ***p < 0.001 vs. Sham and GSNO, +++p < 0.001 vs.
TBI.
Khan et al. Journal of Neuroinflammation 2011, 8:78
http://www.jneuroinflammation.com/content/8/1/78
Page 11 of 17GSNO increases the expression of BDNF, TrkB, and
synaptophysin in the traumatic penumbra region
following TBI
Synaptic plasticity and neurotrophic factors (expression
of synaptophysin, BDNF, TrkB) are involved in neurore-
pair activity, leading to functional recovery following
acute brain injury [76-78]. While the expression of
synaptophysin is related with synaptogenesis, the expres-
sion of BDNF and its receptor TrkB supports neuron
survival and axon growth after neuronal injury [76]. We
examined whether GSNO induces the neurotrophic fac-
tors and enhances their expression, thereby contributing
to the overall neurorepair process. The expression was
determined in the fixed sections at 14 days after TBI in
the traumatic penumbra. The expression of synaptophy-
sin (Figure 10A), BDNF (Figure 10B) and TrkB (Figure
10C) was remarkably decreased in the TBI brain com-
pared to sham. The GSNO-treated brains showed
intense expression of synaptophysin, BDNF, and TrkB
compared to the TBI brains (Figure 10 A-C).
Discussion
Following TBI, 3-NT (peroxynitrite) is formed early in
and around the vessels (Figure 1) and in plasma (Figure
3A). The expression of 3-NT remains increased in neu-
rons as well as in endothelial cells even two weeks after
TBI (Figure 2). The increased 3-NT levels (Figures 1, 2,
3) correlated with the levels of lipid peroxidation pro-
ducts in both brain and plasma (Figure 4). While GSNO
treatment of TBI animals significantly reduces the levels
of 3-NT and lipid peroxidation products (Figures 1, 2, 3,
4), SIN-1 (a peroxynitrite forming agent) treatment sig-
nificantly increases the levels of peroxynitrite (Figure
3A) and TBARS (Figure 4) in plasma compared to the
TBI group. Furthermore, SIN-1 treatment of TBI
increases BBB leakage (Figure 5A), edema (Figure 5C),
Figure 9 Effect of GSNO on reduction of inflammation, demyelination and axonal loss at 14
th day after TBI. IHC photomicrographs of
H&E staining (A) show enhanced inflammatory infiltration in the traumatic penumbra region of TBI group compared with GSNO group. Sham
group does not show infiltration. LFB (B) and Bielschowsky silver (C) stainings show loss of myelin and axons respectively in the traumatic
penumbra region. Treatment with GSNO reduced the loss of myelin and damage to axons. The sham brain does not show loss of myelin or
axons. Photomicrographs are representative of n = 3 in each group.
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involvement of peroxynitrite in TBI-induced neurovas-
cular pathology. Also, SIN-1 treatment of TBI remark-
ably decreases and GSNO significantly increases the
levels of NO (Figure 3B) and GSH compared to TBI
(Figure 8), indicating an association of antioxidant activ-
ity with GSNO. This antioxidant activity of GSNO
might be responsible, at least in part, for its neurovascu-
lar protective ability. In the long-term two-week study,
GSNO treatment of TBI stimulated the neurorepair
mechanisms by blocking the loss of myelin/axons (Fig-
ure 9) and enhancing the expression of both synapto-
physin and neurotrophic factors such as BDNF and its
high affinity receptor TrkB (Figure 10).
The deleterious role of peroxynitrite in both IR and
TBI is accepted because the scavenging of peroxynitrite
has resulted in neurovascular protection [41,42,67,71,79].
However, reducing peroxynitrite for therapeutic purposes
by GSNO has an advantage over reported metal-based
synthetic scavengers [42,80] because GSNO is an endo-
genous molecule of the human body and it is metabo-
lized ultimately into beneficial -SNO/NO and GSH [18].
In the traumatized brain, NO bioavailability decreases
early due to its conversion to peroxynitrite as shown in
Figure 3. Once formed, peroxynitrite uncouples eNOS
via oxidizing and depleting either the eNOS substrate L-
arginine, the cofactor tetrahydrobiopterin, or both.
Uncoupled eNOS produces more superoxide than NO,
resulting in reduced NO levels and the formation of
increasing amounts of peroxynitrite in the same compart-
ment. This uncoupling of eNOS via peroxynitrite may
lead to endothelial cell activation and enhanced expres-
sion of ICAM-1, thus compromising BBB integrity (Fig-
ure 5A-B) and causing a neuroinflammatory secondary
Figure 10 Effect of GSNO on enhanced expression of synaptophysin, BDNF, and TrkB at 14
th day after TBI. IHC photomicrographs show
reduced expression of synaptophysin (A, red fluorescence), BDNF (B, brown diaminobenzidine staining), and TrkB (C, red fluorescence) in the
traumatic penumbra region of the TBI group. Sham and GSNO groups show enhanced expression of synaptophysin, BDNF and TrkB compared
to the TBI group. Photomicrographs are representative of n = 3 in each group.
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Inflammation-induced monocyte-endothelial cell interac-
tion and up regulation of ICAM-1 have been reported to
be inhibited by GSNO-mediated S-nitrosylation of NF-
B [17], indicating that GSNO invokes its anti-inflamma-
tory effect through S-nitrosylation. eNOS is also reported
to be dynamically regulated by S-nitrosylation at Cys
101,
resulting in inhibition of eNOS activity [81,82]. There-
fore, GSNO-mediated reduced levels of peroxynitrite for-
mation (Figures 1, 2, 3) and the consequent BBB
protection (Figure 5) may have resulted from the inhibi-
tion of aberrant eNOS by S-nitrosylation. The protective
effect of S-nitrosylation signaling is well documented in
the cardiovascular system [83]. A depletion of circulating
nitroso/nitrosyl species in plasma has been observed in
patients with endothelial dysfunction [84]. Deficient S-
nitrosylation is considered a general mechanism in neu-
rodegenerative diseases [27,85-87]. GSNO also inhibits
platelet activation [22,23] and protects BBB integrity and
epithelial permeability [2,88]. Like endothelial cells, neu-
ronal cells also produced peroxynitrite (Figure 2B), which
may induce cell death, thus compromising neurorepair.
GSNO treatment of TBI also reduced these neuronal per-
oxynitrite levels, likely via nitrosylating and inhibiting
neuronal NOS activity, thereby stimulating neurorepair
mechanisms. Neuronal NOS activity has been shown to
be down regulated by GSNO via nitrosylation of the
NMDA receptor [89].
In vivo, the action of GSNO is modulated mainly by
nitrosylation/transnitrosylation [7,8,18]. Via nitrosylation,
GSNO exerts its anti-inflammatory action mainly
through inhibition of NF-B, TNF-a, and iNOS/neuronal
NOS [3,16,90,91], its antiapoptotic action through inhibi-
tion of caspase-3 activity [19], and its antioxidant activity
through down regulation of peroxynitrite [20,21] and up
regulation of GSH [4]. Another target of GSNO might be
the inhibition of superoxide production by nitrosylation
of NADPH oxidase. Nitrosylation of p47phox of NADPH
oxidase has been reported to suppress superoxide pro-
duction in human endothelial cells [92]. Superoxide is
implicated in the reduction of GSNO because NO has
higher reactivity with superoxide than GSH, a substrate
of GSNO biosynthesis. Reduced levels of GSNO may also
result from its decomposition (denitrosylation) by the
enhanced expression of GSNO reductase [8]. The expres-
sion of GSNO reductase is increased during inflamma-
tion [8]. GSNO reductase is the only known enzyme that
degrades GSNO without releasing NO. Therefore, an
exogenous supplementation of GSNO under neuroin-
flammatory conditions may reduce the oxidative burden
(Figures 4, 8) and protect BBB integrity (Figure 5A-B),
resulting in reduced edema (Figure 5C) and decreased
brain damage (Figures 7, 9). Moreover, GSNO/hemoglo-
bin homeostasis is required in the circulation to maintain
GSNO-based S-nitrosylation mechanisms. Enhancing
S-nitrosylation by ethyl nitrite, a nitrosylating agent of
hemoglobin, has improved outcomes in mice with subar-
achnoid hemorrhage [93].
Our previous study on neurovascular protection by S-
nitrosylating agents in TBI and stroke shows that GSNO
down regulated the expression of inflammatory media-
tors ICAM-1, ED-1, iNOS, MMP-9, protected the BBB,
and improved neurological functions [2,3]. In this study,
we observed that a long-term post-TBI treatment with
GSNO not only improved tissue structure (Figures 7, 9),
reduced the expression of ICAM-1 (Figure 6), and
restored myelin/axon loss (Figure 9) but also increased
synaptogenesis (increased expression of synaptophysin;
Figure 10) and stimulated the expression of neurotrophic
factors (enhanced expression of BDNF and TrkB; Figure
10). Neurorepair following brain injury is facilitated by
synaptophysin and BDNF [94,95]. Synaptophysin is a
protein involved in the biogenesis of synaptic vesicles
and budding. NO can influence plastic changes in speci-
fic brain regions and can change the expression of synap-
tophysin [95]. Because NO is converted to peroxynitrite
in an oxidative environment such as that which occurs in
TBI, it is difficult to dissect the effects on neurotrophins
of NO/peroxynitrite vs. nitrosylation. However, our data
showing enhanced expression of synaptophysin, BDNF
and TrkB in the GSNO brain compared to the TBI (Fig-
ure 10) indicate that nitrosylation accelerates the neuror-
epair process. Preservation of myelin and axons in the
GSNO group (Figure 9) further supports GSNO-
mediated mechanisms of neurorecovery.
The therapeutic potential of GSNO is also supported
by increased levels of GSH and TGSH in the GSNO
brain following TBI (Figure 8). Higher levels of TGSH
in the GSNO group compared to TBI and SIN-1 are
likely due to increased GSSG, which may be converted
back to GSH by GSH reductase. GSNO may also
increase GSH indirectly via neutralizing ROS. A similar
observation after GSNO treatment in our IR study [4]
indicates that GSNO’s infarct-reducing effect (Figure 7)
may be dependent on its antioxidant activity.
Because clinically proven TBI therapy is not currently
available and GSNO shows clinically relevant therapeu-
tic potential in our animal model of TBI, a further
investigation is warranted to test GSNO’se f f i c a c yi n
human TBI. GSNO occurs naturally in the human body
and is safe, as its exogenous administration in humans
for other indications was not associated with toxicity or
side effects [24,26,96].
Conclusion
GSNO reduces peroxynitrite and neuroinflammation,
increases NO and GSH, and protects the integrity of the
BBB and the neurovascular unit following TBI.
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rorepair in the injured animals. Therefore, GSNO has
therapeutic potential to be investigated in human TBI.
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